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Background: The number of 30-year-old or younger patients with breast cancer is increasing. The aim was to
describe the clinicopathological features and prognosis of 30-year-old or younger patients with breast cancer.
Methods: We reviewed the records of 1,406 consecutive patients aged ≤50 years with first diagnosis of invasive
breast cancer referred to surgery from March 2001 to March 2009. A total of 105 patients were aged ≤30 years
(group I) and 1,301 were aged 31–50 years (group II).
Results: Compared with patients of group II, patients of group I had a higher percentage of tumors classified as
estrogen receptors (ER) negative (P < 0.001) and progesterone receptors (PR) negative (P = 0.043), with a Ki-67
labeling index ≥20% of the cells (P = 0.011). There was no difference between the two groups for pT and pN, histology,
endocrine therapy, and chemotherapy. The 5-year survival of group I was 67.5% as compared with 75.3% for group II
(P = 0.003).
Conclusions: Compared with patients aged between 31 and 50 years, patients aged ≤30 years have a greater chance
of having an endocrine-unresponsive tumor and a significantly poor prognosis.
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In China, breast cancer is the most commonly diagnosed
cancer in women. Breast cancer rarely occurs in young
women. Breast cancer before the age of 50 is relatively
uncommon, nevertheless, 15%–25% of all women diag-
nosed with breast cancer are in their thirties or forties
[1]. Furthermore, about 2%–4.8% of the patients with
breast cancer are <35 years old at diagnosis [1,2]. In
Asian, about 9.5%–12% of the patients with breast can-
cer are <35 years old at diagnosis [3]. Breast cancer at a
very young age has been reported to have a more aggres-
sive biological behavior compared with the disease in
older patients. Specifically, in previously published re-
ports, the tumors progress faster, present with higher
grade, and are more often estrogen receptors (ER) nega-
tive than the tumors in older patients [1,4,5].
One population-based study revealed a relationship
between age at diagnosis and risk of death, with the
youngest having a higher risk than patients of intermedi-* Correspondence: lndlxjp@163.com
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unless otherwise stated.ate age [6]. Furthermore, a review of the National
Cancer DataBase has shown that younger patients had
more advanced disease at diagnosis and a poorer 5-year
survival than older premenopausal patients [7]. How-
ever, other studies have revealed that age is not related
to overall or disease-free survival after adjustment for
other prognostic variables [8,9]. Several authors have
even reported that young patients have better survival
[10,11]. In addition, data on treatment effects are
largely dependent upon older series collected over sev-
eral years and extrapolation of data from older age
cohorts. Staging procedure and immunohistochemical
determination of ER and progesterone receptors (PR)
are features that underwent a more or less substantial
change in recent years.
In the present study, we have aimed to investigate the
most recently available details of clinicopathological fea-
tures and prognosis of very young patients (≤30 years of
age) with breast cancer.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,








(n = 1,301; %)
P value
pT stage
pT1 55 (52.4) 754 (58.0)
pT2 44 (41.9) 456 (35.0)
pT3/4 6 (5.7) 91 (7.0) 0.361
pN stage
pN0 43 (41.0) 561 (43.1)
pN1 31 (29.5) 392 (30.1)
pN2 17 (16.2) 172 (13.2)
pN3 14 (13.3) 176 (13.5) 0.859
ER level
Percentage ER <10% 41 (39.0) 275 (21.1)
Percentage ER ≥10% 64 (61.0) 1,026 (78.9) <0.001
PR level
Percentage PR <10% 49 (46.7) 478 (36.7)
Percentage PR ≥10% 56 (53.3) 823 (63.3) 0.043
Ki-67 level
Percentage Ki-67 < 20% 30 (28.6) 536 (41.2)
Percentage Ki-67≥ 20% 75 (71.4) 765 (58.8) 0.011
Histology
Ductal 93 (88.6) 1,098 (84.4)
Lobular 3 (2.9) 88 (6.8)
Other 9 (8.6) 115 (8.8) 0.287
Endocrine therapy
Yes 54 (51.4) 769 (59.1)
No 51 (48.6) 532 (40.9) 0.124
Chemotherapy
Yes 73 (69.5) 865 (66.5)
No 32 (30.5) 436 (33.5) 0.525
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Patients
We analyzed data from 3,152 patients with histologically
proven breast cancer operated on in our institution be-
tween March 2001 and March 2009. Information on the
patient’s pT stage, pN stage, ER level, PR level, Ki-67
level, histology, endocrine therapy, and chemotherapy
were obtained from the hospital records. We divided
3,152 patients into three age groups ≤30 years, 31–50
years, and >50 years. In the present study, we compared
clinicopathological features and prognosis in two groups
of patients: age ≤30 years and age between 31 and
50 years. Informed consent had been obtained, and the
Ethics Committee of Dalian University approved this
study.
Patient follow-up lasted until death or the cutoff date
of March 31, 2014. Generally, patients return every
3 months for the first year, every 6 months for the next
2 years, and after 3 years every 12 months for life. For
all patients, at the time of the last follow-up, 122 pa-
tients (3.9%) had been lost to follow-up. Only patients
who died of breast cancer were regarded as tumor-
related death cases.
Statistical analysis
Statistical comparisons for significance were performed
with the chi-square test for discrete variables. The
Kaplan-Meier method was used for calculating cumula-
tive survival rate, and the difference between groups was
assessed by using the log-rank test. The accepted level of
significance was P < 0.05. All data analysis was per-
formed using the SPSS for Windows, Version 13.0 soft-
ware package.
Results
We analyzed data from 3,152 patients divided into three
age groups: ≤30 years (group I: n = 105), 31–50 years
(group II: n = 1301), and >50 years (groups III: n = 1746).
We compared clinicopathological features and prognosis
in two groups of patients: age ≤30 years and age between
31 and 50 years.
Table 1 shows the clinicopathological factors for group
I as opposed to group II. There were statistical differ-
ences in ER level, PR level, and Ki-67 level between the
two age groups. In group I, when compared with group
II, there were higher percentages of tumors classified as
ER negative (39.0% versus 21.1%, P < 0.001), PR negative
(46.7% versus 36.7%, P = 0.043), with a Ki-67 labeling
index ≥20% of the cells (71.4% versus 58.8%, P = 0.011)
(Table 1).
No statistically significant difference was observed
for the stage of disease at diagnosis [according to the
tumor-node-metastasis (TNM)] [12], for pT and pN
stage. In fact, pT1 was registered in 52.4% and 58.0% ofthe patients in the two groups, respectively. Similarly,
29.5% and 30.1% had one to three lymph nodes involved
and 13.3% and 13.5% had ≥10 nodes in the two groups,
respectively. For the histology, endocrine therapy, and
chemotherapy, there was no significant difference be-
tween the two age groups.
The 5-year survival rates of patients, according to age,
are shown in Table 2. The 5-year survival of group I was
67.5% as compared with 75.3% for group II (P = 0.003).
Discussion
Breast cancer that develops at a young age is commonly
considered to be different from that arising in older pre-
menopausal patients. Tumors occurring in very young
patients are reported to have a particularly aggressive
Table 2 Five-year survival rates according to age group
Age (years) Number of patients 5-year survival rate (%) P value
≤30 105 67.5
31–50 1,301 75.3 0.003
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prognosis, which was described extensively in the pre-
adjuvant systemic therapy era [6]. Data of our study
were derived from our hospital records with information
on the most important prognostic variables such as
tumor size, lymph node status, and histology. We could
not evaluate the risk of recurrence according to age be-
cause our hospital records did not routinely collect this
information. In the study, there was no difference be-
tween the two age groups for pT and pN, histology,
endocrine therapy, and chemotherapy. Compared with
patients aged between 31 and 50 years, patients aged
≤30 years have a greater chance of having an endocrine-
unresponsive tumor and a significantly poor prognosis.
Because of the lower probability of having breast can-
cer at young age, both women and physicians might per-
form self-examination or clinical examination less often
and minimize putative abnormalities [13]. Owing to the
fact that the breast tissue of younger women is denser, it
is more difficult to examine clinically and by mammog-
raphy. Diagnosis is often delayed in young women, and
cancers are larger and more advanced [4,8]. A more ad-
vanced stage at diagnosis may also reflect a rapidly
growing tumor. Special endocrine and immunological
factors and/or genetic differences more frequent in
younger women who develop breast cancer may be
linked to tumor invasiveness [14]. For breast cancer, the
TNM stage proved to be the most significant independ-
ent prognostic factor for determining survival. In our
study, there was no difference between the two age
groups for pT and pN, thus not supporting previous data
indicating more advanced disease in younger patients at
diagnosis of operable disease. The result is similar to
that of Colleoni et al. [1].
Several studies have shown that survival among young
women is worse than that of older women [4,15,16].
However, in some of these studies, the observations are
drawn from a single hospital and selection may have
taken place during the process of referring patients to
the hospital [15,16]. Furthermore, some authors have
reported that there is no difference in survival by age at
diagnosis [8,9]. In the present study, compared with
patients aged between 31 and 50 years, patients aged
≤30 years have a significantly poor prognosis. Our find-
ings are consistent with other population-based studies
showing difference in survival by age at diagnosis [6,7].
Histology was found to be prognostic in breast cancer.
Lobular cancer had a better prognosis than ductal cancerfor separate or combined stages [11]. Mclaughlin et al.
reported that lobular cancer had a better prognosis than
ductal cancer for combined stages [17]. In the present
study, for the histology, there was no significant differ-
ence between the two age groups.
Current guidelines consider breast cancer patients age
<35 years at high risk of relapse and/or mortality and
recommend adjuvant chemotherapy irrespective of the
stage of their tumor [18]. Moreover, Kroman et al. [9]
have clearly demonstrated the unfavorable effect of
young age in patients having no adjuvant therapy. In our
study, almost 70% of the women aged ≤30 years received
adjuvant chemotherapy. Furthermore, one retrospective
analysis on treatment outcome leads to the hypothesis
that the endocrine effects of chemotherapy alone were
insufficient for patients in the younger age group with
endocrine-responsive tumors, for whom suppression of
estradiol production might be essential [19]. On the
other hand, endocrine therapies are not easy to offer to
very young patients [20,21], and further investigations in
this specific field are urgently needed [22].Conclusions
Compared with patients aged between 31 and 50 years,
patients aged ≤30 years have a greater chance of having
an endocrine-unresponsive tumor and a significantly
poor prognosis. Pathological tumor size, lymph node
metastasis, and histology have a similar distribution
among the younger and the older cohorts, thus not sup-
porting previous data indicating more advanced disease
in younger patients at diagnosis of operable disease.
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